NCT04562311View on ClinicalTrials.gov

Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

August 30, 2024

Study Completion Date

October 30, 2025

Conditions
Bladder Cancer Stage IV
Interventions
DRUG

Chidamide

Chidamide: 30mg orally BIW. Immunotherapy: tislelizumab,the fixed dose of 200 mg IV. Treatment cycles are repeated every 3 weeks.

Trial Locations (1)

510060

Cancer Center, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER